Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC

Clinical trial NCT04524689 · TERMINATED

Trial details

NCT number: NCT04524689
Sponsor: Sanofi
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)

Start date: 2020-10-26
Primary completion: 2024-03-12
Enrollment: 57

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.